UK ad­vis­es against cov­er­ing No­var­tis' Kym­ri­ah for adults; Ex-Mast chief Bri­an Cul­ley ap­point­ed CEO at Bi­o­Time

→ Right on the heels of en­dors­ing the use of No­var­tis’ CAR-T Kym­ri­ah in chil­dren, the UK drug price watch­dog NICE is turn­ing its thumbs down for ex­tend­ing its wel­come to adults. “How­ev­er, NICE does recog­nise that No­var­tis’ ti­s­agen­le­cleu­cel-T, al­so known as Kym­ri­ah, has sig­nif­i­cant clin­i­cal ben­e­fits, and would wel­come fur­ther dis­cus­sions on its cost-ef­fec­tive­ness.”

→ De­gen­er­a­tive dis­ease spe­cial­ist Bi­o­Time $BTX has tapped Bri­an Cul­ley as its new CEO, tak­ing up a role pre­vi­ous­ly shared by Adi Mo­han­ty and Michael West. Cul­ley helmed Mast Ther­a­peu­tics for sev­en years be­fore a failed lead pro­gram dragged it down and left it with lit­tle op­tion oth­er than serv­ing as a shell for Savara’s re­verse merg­er. West will now move on­to the chief ex­ec­u­tive role at AgeX, a Bi­o­Time af­fil­i­ate fo­cused on age-re­lat­ed de­gen­er­a­tive ail­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.